Introduction
MAS is a severe complication of rheumatic diseases, mostly sJIA. Clinical and laboratory features are similar to those of FHL resulting from mutations in selected genes involved in the cytotoxicity pathway.
Objectives
We investigated the presence of mutations of FHL-related genes and of abnormalities in degranulation and perforin expression, in patients with MAS occurring in the context of sJIA.
Methods
From the HLH Italian National Registry, we selected patients with MAS defined according to the HLH 2004 criteria and with confirmed diagnosis of sJIA based on ILAR criteria. Mutation analysis was performed by Sanger sequencing of FHL-related genes. Perforin expression and degranulation were analyzed using flow-cytometry.
Results
We identified 31patients (17 females; 25 Southern European, 6 Indian) with MAS and sJIA. Eleven patients (35.5%) had 14 monoallelic mutations in PRF1 (n=7), UNC13D (n=1), STX11 (n=1), STXBP2 (n=4), and Rab27a (n=1). Three patients had mutations in 2 genes. Both degranulation and perforin expression were evaluated in 18 patients. At least one test was defective in 11 patients (61%). The clinical and laboratory features of patients with monoallelic mutation and/or with abnormalities in at least one functional test, were not different from those of the remaining patients. However, re-occurrence of MAS tended to be more frequent in patients carrying mutations (mutated 27% versus non-mutated 10%) and in patients showing abnormalities in at least 1 functional test (abnormal 18% versus 0%). One patient died of MAS: she carried the N252S PRF1 variant and showed reduced perforin expression.
Conclusion
Monoallelic mutations in FHL-related genes and partial defect in either perforin expression or degranulation capacity are frequently observed in patients with sJIA who develop MAS. Additional genetic studies are warranted to identify additional genes potentially linked to MAS development. 
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